Clinical Trial

A Clinical Trial to Assess the Pharmacokinetics and Safety of AD-229 Compared to AD-2291 in Healthy Adults

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated February 27, 2026 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
The study compare and evaluate the safety and pharmacokinetic characteristics between the administration of AD-229 and the administration of AD-2291 in healthy adults.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-27.
Trial Details
NCT Number NCT07385248
Lead Sponsor Addpharma Inc.
Conditions Gastritis
Enrollment 28 participants
Start Date 2026-04
Primary Completion 2026-06 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2026-02-27